A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Inclusion Criteria: * 12 to 35 years old(inclusive) male or female subjects at the time of informed consenting. For minors, their legal representative is required to sign the informed consent form, besides, if the subjects aged 8 years or older, they should provide a signed and dated. * Diagnosis of β-thalassemia major. * Generally in good condition, Karnofsky performance score≥60 points for subjects≥16 years old, or Lansky Play-Performance score≥60 points for subjects under 16 years old. * For female subjects of childbearing potential: use effective contraceptive measures from the start of screening and agree to continue using such measures for contraception throughout the study * For male subjects who have a potential ability to father a child: use condoms or other methods continuously from the start of mobilization to ensure effective contraception for sexual partners during the study period Exclusion Criteria: * Treatment with other investigational medications or other experimental interventions 30 days prior to signing informed consent or within 6 half-lives of the drug, whichever is longer * Subjects who have received or are receiving thalidomide and/or Luspatercept in the past 6 months before screening * Previously received allogeneic hematopoietic stem cell transplantation or gene(edited) therapy * Subjects have available related fully matching donors and are eligible and prepared for allogeneic hematopoietic stem cell transplantation * Patients with coexisting α-t…